Radioimmunodetection of prostatic cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging
- 5 August 1983
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 250 (5) , 630-635
- https://doi.org/10.1001/jama.250.5.630
Abstract
Radioimmunodetection (RAID) of prostatic cancer is done by injecting 131I-labeled rabbit antibody IgG against prostatic acid phosphatase (PAP) and performing total-body photoscans with a .gamma. scintillation camera. Of 2 patients tested, the PAP RAID scintiscans located the primary or recurrent prostatic cancers in both and showed no disease in the lungs of the patient shown subsequently to have lung cancer. The lung tumor nodules showing anti-PAP IgG accretion were assumed to be of prostatic cancer origin, since one of the original tumors removed from this patient''s other lung a year earlier stained for PAP by immunohistochemistry. PAP RAID can locate primary and metastatic tumors of prostatic origin.This publication has 3 references indexed in Scilit: